Is Syneos Health, Inc. (NASDAQ:SYNH) Potentially Undervalued?

Syneos Health, Inc. (NASDAQ:SYNH), which is in the life sciences business, and is based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGS. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Let’s take a look at Syneos Health’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for Syneos Health

What’s the opportunity in Syneos Health?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 4.2% below my intrinsic value, which means if you buy Syneos Health today, you’d be paying a fair price for it. And if you believe the company’s true value is $47.35, then there isn’t much room for the share price grow beyond what it’s currently trading. What’s more, Syneos Health’s share price may be more stable over time (relative to the market), as indicated by its low beta.

What does the future of Syneos Health look like?

NasdaqGS:SYNH Future Profit January 10th 19
NasdaqGS:SYNH Future Profit January 10th 19
Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. In Syneos Health’s case, its revenues over the next few years are expected to grow by 30%, indicating a highly optimistic future ahead. If expense does not increase by the same rate, or higher, this top line growth should lead to stronger cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? SYNH’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping tabs on SYNH, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Syneos Health. You can find everything you need to know about Syneos Health in the latest infographic research report. If you are no longer interested in Syneos Health, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at